Pancreatic Cancer Research

ResearcherUniversity of MinnesotaNo recent work listed

Lei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1802-7466; OpenAlex author ID A5100436098. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: 1 paper

Papers 10

  1. Characterization of Novel Murine and Human PDAC Cell Models: Identifying the Role of Intestine Specific Homeobox Gene ISX in Hypoxia and Disease Progression. Co-author DOI 10.1016/j.tranon.2019.05.002↗
  2. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Co-author DOI 10.1038/s41598-017-00288-4↗
  3. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes. Co-author DOI 10.18632/oncotarget.16249↗
  4. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Co-author DOI 10.18632/oncotarget.16633↗
  5. Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients. Co-author DOI 10.18632/oncotarget.12447↗
  6. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.7663↗
  7. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep10081↗
  8. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1159/000369686↗
  9. Methylseleninic acid suppresses pancreatic cancer growth involving multiple pathways. Co-author DOI 10.1080/01635581.2014.868911↗
  10. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. Last author DOI 10.3892/ijo.2014.2568↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liwei Wang · 7 shared papers, 2014–2017 · strength 0.45
  2. Hai Xia Hu · 5 shared papers, 2014–2017 · strength 0.31
  3. Feng Jiao · 4 shared papers, 2014–2017 · strength 0.25
  4. Meng Zhuo · 3 shared papers, 2016–2017 · strength 0.20
  5. Ting Han · 3 shared papers, 2016–2017 · strength 0.20
  6. Leilei Wu · 2 shared papers, 2017 · strength 0.14
  7. Weifeng Song · 2 shared papers, 2015 · strength 0.14
  8. Haiyan Yang · 2 shared papers, 2016 · strength 0.12
  9. Arsheed Ahmad Ganaie · 1 shared paper, 2019 · strength 0.08
  10. Dezhong Joshua Liao · 1 shared paper, 2019 · strength 0.08
  11. Mohammad Saleem Bhat · 1 shared paper, 2019 · strength 0.08
  12. Yufen Zhou · 1 shared paper, 2017 · strength 0.08
  13. Xiangyi He · 1 shared paper, 2017 · strength 0.08
  14. Yongping Zhang · 1 shared paper, 2017 · strength 0.08
  15. Yaozong Yuan · 1 shared paper, 2017 · strength 0.08
  16. Jiujie Cui · 1 shared paper, 2017 · strength 0.07
  17. Lixia Wu · 1 shared paper, 2017 · strength 0.07
  18. Weiyi Huang · 1 shared paper, 2015 · strength 0.06
  19. Jiong Hu · 1 shared paper, 2016 · strength 0.06
  20. Junjie Hang · 1 shared paper, 2016 · strength 0.06
  21. Junxuan Lü · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.